TECVAYLI demonstrates potential as frontline combination therapy for patients with newly diagnosed
100 percent of evaluable patients for minimal residual disease (MRD) testing achieved MRD negativity in MajesTEC-5 as induction therapy and MajesTEC-4 as maintenance therapy Johnson & Johnson today announced...
